Monoclonal antibodies - 61 News from the business & finance department for the pharma industry

Tip: You can further refine your news selection by organizations and countries.

Monoclonal antibodies - 61 News from the business & finance department for the pharma industry

Tip: You can further refine your news selection by organizations and countries.

image description

Novel anti-cancer therapy: Prevention or reversal of cancer resistance

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

18-Jul-2024 - CatalYm announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, ...

monoclonal antibodies bladder cancer cancer
image description

SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

Novel and potentially groundbreaking therapeutic strategy

10-Jul-2024 - SciRhom GmbH announced the closing of a EUR 63 million (USD 70 million) Series A financing round. The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including ...

monoclonal antibodies autoimmune diseases biopharmaceuticals
image description

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases

01-Feb-2024 - Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, announced their merger to form Calluna Pharma Inc. (Calluna). Calluna has raised EUR 75 million in a series A financing ...

monoclonal antibodies asthma chronic renal disease
image description

CatalYm Closes EUR 50 Million Series C Financing

Start-up develops a "new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape"

24-Nov-2022 - CatalYm announced the close of a EUR50 million (USD49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, ...

monoclonal antibodies cancer cancer immunotherapeutics
image description

Merck Boosts Commercial Capacity in France

Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France

04-Oct-2022 - Merck has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France. The 2,700-square-meter facility will provide global supply of commercial drug substances, including monoclonal antibodies (mAbs) and other recombinant proteins, from ...

monoclonal antibodies contract development contract services
image description

GSK and CureVac announce strategic mRNA technology collaboration

Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases

21-Jul-2020 - GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements ...

monoclonal antibodies infectious diseases mrna therapeutics

Swiss-French biotech start-up launches

ALENTIS Therapeutics raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer

02-May-2019 - ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the ...

monoclonal antibodies cancer drug design

MorphoSys received a milestone payment from Janssen

Janssen has Expanded Clinical Development of Guselkumab into Familial Adenomatous Polyposis

17-Apr-2019 - MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab (Tremfya(R)) into familial adenomatous polyposis (FAP), a disease of the gastrointestinal tract. Janssen has initiated a phase 1b proof-of-concept clinical ...

monoclonal antibodies bowel cancer colon cancer

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals

Gains full-rights to Cormorant’s HuMax-IL8 antibody program and lead asset HuMax-IL8 in Phase 1/2 Development

06-Jul-2016 - Bristol-Myers Squibb Company and Cormorant Pharmaceuticals announced that Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The ...

monoclonal antibodies interleukins

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration

Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies

29-Jul-2015 - Sanofi and Regeneron Pharmaceuticals, Inc. have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. As part of the agreement, the two companies will jointly develop a programmed cell death protein ...

monoclonal antibodies immuno-oncology oncology
Search all

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,276 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now